Cargando…
IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome
Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype awai...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876612/ https://www.ncbi.nlm.nih.gov/pubmed/36577365 http://dx.doi.org/10.1016/j.celrep.2022.111883 |
_version_ | 1784878200945377280 |
---|---|
author | Araya, Paula Kinning, Kohl T. Coughlan, Christina Smith, Keith P. Granrath, Ross E. Enriquez-Estrada, Belinda A. Worek, Kayleigh Sullivan, Kelly D. Rachubinski, Angela L. Wolter-Warmerdam, Kristine Hickey, Francis Galbraith, Matthew D. Potter, Huntington Espinosa, Joaquin M. |
author_facet | Araya, Paula Kinning, Kohl T. Coughlan, Christina Smith, Keith P. Granrath, Ross E. Enriquez-Estrada, Belinda A. Worek, Kayleigh Sullivan, Kelly D. Rachubinski, Angela L. Wolter-Warmerdam, Kristine Hickey, Francis Galbraith, Matthew D. Potter, Huntington Espinosa, Joaquin M. |
author_sort | Araya, Paula |
collection | PubMed |
description | Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype await elucidation. Here we report a multi-omics analysis of neurodegeneration and neuroinflammation biomarkers, plasma proteomics, and immune profiling in a diverse cohort of more than 400 research participants. We identified depletion of insulin growth factor 1 (IGF1), a master regulator of growth and brain development, as the top biosignature associated with neurodegeneration in DS. Individuals with T21 display chronic IGF1 deficiency downstream of growth hormone production, associated with a specific inflammatory profile involving elevated tumor necrosis factor alpha (TNF-α). Shorter children with DS show stronger IGF1 deficiency, elevated biomarkers of neurodegeneration, and increased prevalence of autism and other conditions. These results point to disruption of IGF1 signaling as a potential contributor to stunted growth and neurodegeneration in DS. |
format | Online Article Text |
id | pubmed-9876612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-98766122023-01-25 IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome Araya, Paula Kinning, Kohl T. Coughlan, Christina Smith, Keith P. Granrath, Ross E. Enriquez-Estrada, Belinda A. Worek, Kayleigh Sullivan, Kelly D. Rachubinski, Angela L. Wolter-Warmerdam, Kristine Hickey, Francis Galbraith, Matthew D. Potter, Huntington Espinosa, Joaquin M. Cell Rep Article Down syndrome (DS), the genetic condition caused by trisomy 21 (T21), is characterized by stunted growth, cognitive impairment, and increased risk of diverse neurological conditions. Although signs of lifelong neurodegeneration are well documented in DS, the mechanisms underlying this phenotype await elucidation. Here we report a multi-omics analysis of neurodegeneration and neuroinflammation biomarkers, plasma proteomics, and immune profiling in a diverse cohort of more than 400 research participants. We identified depletion of insulin growth factor 1 (IGF1), a master regulator of growth and brain development, as the top biosignature associated with neurodegeneration in DS. Individuals with T21 display chronic IGF1 deficiency downstream of growth hormone production, associated with a specific inflammatory profile involving elevated tumor necrosis factor alpha (TNF-α). Shorter children with DS show stronger IGF1 deficiency, elevated biomarkers of neurodegeneration, and increased prevalence of autism and other conditions. These results point to disruption of IGF1 signaling as a potential contributor to stunted growth and neurodegeneration in DS. 2022-12-27 /pmc/articles/PMC9876612/ /pubmed/36577365 http://dx.doi.org/10.1016/j.celrep.2022.111883 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ). |
spellingShingle | Article Araya, Paula Kinning, Kohl T. Coughlan, Christina Smith, Keith P. Granrath, Ross E. Enriquez-Estrada, Belinda A. Worek, Kayleigh Sullivan, Kelly D. Rachubinski, Angela L. Wolter-Warmerdam, Kristine Hickey, Francis Galbraith, Matthew D. Potter, Huntington Espinosa, Joaquin M. IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome |
title | IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome |
title_full | IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome |
title_fullStr | IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome |
title_full_unstemmed | IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome |
title_short | IGF1 deficiency integrates stunted growth and neurodegeneration in Down syndrome |
title_sort | igf1 deficiency integrates stunted growth and neurodegeneration in down syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876612/ https://www.ncbi.nlm.nih.gov/pubmed/36577365 http://dx.doi.org/10.1016/j.celrep.2022.111883 |
work_keys_str_mv | AT arayapaula igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT kinningkohlt igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT coughlanchristina igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT smithkeithp igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT granrathrosse igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT enriquezestradabelindaa igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT worekkayleigh igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT sullivankellyd igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT rachubinskiangelal igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT wolterwarmerdamkristine igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT hickeyfrancis igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT galbraithmatthewd igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT potterhuntington igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome AT espinosajoaquinm igf1deficiencyintegratesstuntedgrowthandneurodegenerationindownsyndrome |